Elesclomol's Phase III Fizzle Leaves Synta In Need Of Alternatives
This article was originally published in Pharmaceutical Approvals Monthly
Suspension of Synta/GlaxoSmithKline's Phase III oncology candidate elesclomol amid signs of higher mortality has left developer Synta with a gaping late-stage pipeline hole and in need of a new business plan
You may also be interested in...
Deal for Synta’s CRAC channel inhibitor brings $25 million upfront plus potential for $1 billion in milestones.
Failure casts doubt on Bristol/Medarex’s CTLA-4 inhibitor ipilimumab, analysts say.
Cell Therapeutics completes enrollment in pixantrone Phase III trial; Elixir Pharmaceuticals type 2 drug mitiglinide enters final Phase III; Takeda stops development of cholesterol compound TAK-475 (lapaquistat); more R&D news, in brief